International Clinical Trial: A prospective, single-arm, open-label Phase II clinical study on the efficacy and safety of Serplulimab combined with TPC(Nab-paclitaxel, cisplatin, and capecitabine) regimen as neoadjuvant therapy followed by concurrent chemoradiotherapy in locally advanced cervical cancer

Geneva, Feb. 13 -- International Clinical Trials Registry received information related to the study (ChiCTR2600118532) titled 'A prospective, single-arm, open-label Phase II clinical study on the efficacy and safety of Serplulimab combined with TPC(Nab-paclitaxel, cisplatin, and capecitabine) regimen as neoadjuvant therapy followed by concurrent chemoradiotherapy in locally advanced cervical cancer' on Feb. 6.

Study Type: Interventional study

Study Design: Single arm

Primary Sponsor: Huizhou Central People's Hospital

Condition: Cervical Cancer

Intervention: Intervention group:Serplulimab + Nab-paclitaxel + Cisplatin + Capecitabine for 2 cycles

Recruitment Status: Not Recruiting

Phase: 2

Date of First Enrollment: 2026-02-24 ...